Sanofi enlists Emcure for cancer-drug marketing in India

Shailesh Ayyangar

Sanofi's ($SNY) known for its emerging-markets prowess, but we all need a little help sometimes. To aid it with marketing its oncology lineup in India, the French drugmaker has brought on local company Emcure Pharmaceuticals, PMLiVE reports. Emcure will be responsible for drugs Taxotere, Jevtana, Fludara and Fasturtec, and doctors and patients "will now have access--under one roof--to one of the most comprehensive and complementing oncology portfolios in India," Shailesh Ayyangar, head of Sanofi's Indian subsidiary, told the publication. Report | More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.